Over the years, the biological market has expanded and will continue to grow. Most novel drugs are still not affordable for the general population worldwide. Every multi-million dollar biologic is a result of the high cost of the drug, as opposed to the population it benefits.
We at BRL work tirelessly to ensure that essential, life-saving biologics can become more accessible and affordable for all.
Dr. Bhami Shenoy, PhD
Chief Science Office
Dr. Surya Pai, BDS
Dr. Viren Sarin, PhD
Retd. Distinguished Fellow, Eli Lilly